Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Conmed (CNMD) Research & Development (2016 - 2025)

Conmed (CNMD) has disclosed Research & Development for 2 consecutive years, with $7.2 million as the latest value for Q4 2011.

  • For the quarter ending Q4 2011, Research & Development fell 12.03% year-over-year to $7.2 million, compared with a TTM value of $28.7 million through Dec 2011, changed N/A, and an annual FY2025 reading of $55.9 million, up 2.68% over the prior year.
  • Research & Development was $7.2 million for Q4 2011 at Conmed, up from $7.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $8.1 million in Q4 2010 and bottomed at $6.4 million in Q2 2010.